PlumX Metrics
Embed PlumX Metrics

Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study)

European Respiratory Journal, ISSN: 1399-3003, Vol: 64, Issue: 2
2024
  • 1
    Citations
  • 0
    Usage
  • 23
    Captures
  • 2
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    1
    • Citation Indexes
      1
  • Captures
    23
  • Mentions
    2
    • News Mentions
      2
      • News
        2

Most Recent News

Copenhagen University Hospital Reports Findings in Biologics (OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial)

2024 JUN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Math Daily News -- New research on Biotechnology - Biologics is the subject

Article Description

Background Anti-interleukin (IL)-5 biologics effectively reduce exacerbations and the need for maintenance oral corticosteroids (mOCS) in severe eosinophilic asthma. However, it is unknown how long anti-IL-5 treatment should be continued. Data from clinical trials indicate a gradual but variable loss of control after treatment cessation. In this pilot study of titration, we evaluated a dose-titration algorithm in patients who had achieved clinical control on an anti-IL-5 biologic. Methods In this open-label randomised controlled trial conducted over 52 weeks, patients with clinical control (no exacerbations or mOCS) on anti-IL-5 treatment were randomised to continue with unchanged intervals or have dosing intervals adjusted according to a titration algorithm that gradually extended dosing intervals and reduced them again at signs of loss of disease control. The OPTIMAL algorithm was designed to down-titrate dosing until signs of loss of control, to enable assessment of the longest dosing interval possible. Results Among 73 patients enrolled, 37 patients were randomised to the OPTIMAL titration arm; 78% of patients tolerated down-titration of treatment. Compared to the control arm, the OPTIMAL arm tended to have more exacerbations during the study (32% versus 17%; p=0.13). There were no severe adverse events related to titration, and lung function and symptoms scores remained stable and comparable in both study arms throughout. Conclusion This study serves as a proof of concept for titration of anti-IL-5 biologics in patients with severe asthma with clinical control on treatment, and the OPTIMAL algorithm provides a potential framework for individualising dosing intervals in the future.

Bibliographic Details

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know